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BACKGROUND: Acute myocardial infarction is a leading cause of death worldwide.
Though highly beneficial, reperfusion of myocardium is associated with reperfusion
injury. While indirect inhibition of Factor Xa has been shown to attenuate myocardial
ischemia-reperfusion (I/R) injury, the underlying mechanism remains unclear. Our
study sought to evaluate the effect of rivaroxaban (RIV), a direct inhibitor of Factor
Xa, on myocardial I/R injury and determine its cellular targets.
EXPERIMENTAL APPROACH: We used a rat model of 40-minutes coronary ligation
followed by reperfusion. RIV (3 mg/Kg) was given per os 1 hour before reperfusion.
Infarct size and myocardial proteic expression of survival pathways were assessed at
120 and 30 minutes of reperfusion, respectively. Plasmatic levels of P-selectin and
von Willebrand factor were measured at 60 minutes of reperfusion. Cellular RIV
effects were assessed using hypoxia-reoxygenation (H/R) models on human umbilical
vein endothelial cells and on rat cardiomyoblasts (H9c2 cell line).
KEY RESULTS: RIV decreased infarct size by 21% (42.9% vs. 54.2% in RIV-treated
rats and controls respectively, p < 0.05) at blood concentrations similar to human
therapeutic (387.7 ± 152.3 ng/mL) levels. RIV had no effect on H/R-induced
modulation of endothelial phenotype, nor did it alter myocardial activation of RISK
and SAFE pathways at 30 min after reperfusion. However, RIV exerted a
cytoprotective effect on H9c2 cells submitted to H/R.
CONCLUSION: RIV decreased myocardial I/R injury in rats at concentrations similar
to human therapeutic ones. This protection was not associated with endothelial
phenotype modulation but rather with potential direct cytoprotection on
cardiomyocytes.
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